 Bio-Path Holdings, Inc., BPTH, a biotechnology company leveraging its proprietary DNAbilizeTM liposomal delivery and antisense technology to develop a portfolio of targeted nucleic acid cancer drugs, today announced its financial results for the first quarter ended March 31, 2020 and provided an update on recent corporate developments. In May, Bio-Path announced a virtual poster presentation at the upcoming 2020 American Society of Clinical Oncology ASCO Annual Meeting, taking place from May 29-31, 2020. 